Page 79 - CIBERER2016-ENG

genes. Epigenetic changes at critical regulatory regions and deregulation of specific microRNAs may be instrumental in resolving this complex puzzle. Finally, we are performing in vitro and in vivo (with xenotransplanted mice) preclinical assays in order to reappraise clinical therapeutic strategies.
KEY WORDS: Precursor T-cell lymphoblastic neoplasms (T-ALL/TLBL). Individualized precision medicine. Next-generation sequencing. Intratumoral heterogeneity. RNA editing. MicroRNAs. Cancer exosomes. Epigenomic analyses. Signaling pathways. Critical mutations. Aberrant expression.
Most relevant scientific articles
• Roncero A.M., Lopez-Nieva P., Cobos-Fernandez M.A., Villa-Morales M., Gonzalez-Sanchez L., Lopez- Lorenzo J.L. et al. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia. 2016;30(1):94-103.
• Fernandez-Piqueras J. New mutations for nodal lymphomas of TFH origin. Blood. 2016;128(11):1446- 1447.
• Marin-Rubio J.L., de Arriba M.C., Cobos-Fernandez M.A., Gonzalez-Sanchez L., Ors I., Sastre I. et al. Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma. Oncotarget. 2016;7(38):61485-61499.
• Lopez-Nieva P., Malave M., Gonzalez-Sanchez L., Fernandez-Piqueras J., Fernandez-Navarro P., Santos J. Transcriptomic analysis reveals sex-specific differences in the expression of Dcl1 and Fis1 genes in the radio-adaptive response of thymocytes to TRP53-mediated apoptosis. BMC Genomics. 2016;17(1).
Hightlights
During the year 2016 we have published four articles in high impact journals. The most significant outcomes were: (1) the demonstration of the functional consequences of multiple mutations at the JAK2 gene involved in the development of T-cell lymphoblastic lymphomas, indicating the advisability of using NGS and new treatments (Leukemia; IF. 12,104); (2) a review article published in the journal Blood about the importance of new mutations for nodal lymphomas of TFH origin (Blood; IF: 11,847), and (3) the proposal
of an operational model to classify T-cell lymphoblastic lymphoma according to their aggressiveness (Oncotarget; 5,008). As to investigation projects, it has to be emphasized our involvement in an European project, the direction of an ACCI-CIBERER-16, the direction of a SAF-2015 project, and our engagement in a Grant-Agreement covered by the IIS-FJD to the study of T-cell lymphoblastic lymphoma and the preparation of reports about patient admitted in the Hospital. It should be also noted the direction of several end- of-degree and end-of-master projects; the organization of a Sesión Científica Extraordinaria in the Real Academia Nacional Española de Medicina; our participation in lectures at multiple Specialisation Courses and Masters organized by different institutions (UAM, UCM, UAH, CNIO, CIB/CSIC etc.). Additionally, we have participated in various training courses and meetings organized by the CIBERER and other institutions belonging to the ISCIII. Finally, we would like to comment on our work in the Experts Committee on
Human Genetics (Community of Madrid), and the Chairmanship of the Scientific Advisory Board of the FARPE/FUNDALUCE Foundation, given scientific advise and contributing to the evaluation of their annual Research prize; my incorporation as a member of the External Scientific Committee of the Institute for Health Research of Hospital 12 de Octubre (i+12); y my work as a member of the Executive Committee of the Lección Conmemorativa Jiménez Díaz.
ER
research groups 79